SMMT - Summit Therapeutics Inc.
About Summit Therapeutics Inc. (https://www.smmttx.com)
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Mahkam Zanganeh | Co-CEO, President & Director | 1970 | $1,025,895 GBP |
| Manmeet Singh Soni | Chief Operating Officer, Chief Financial Officer & Director | 1978 | $1,025,895 GBP |
| Robert W. Duggan | Co-CEO & Executive Chairman | 1944 | $172,376 GBP |
| Allen S. Yang | Chief R&D Strategy Officer | 1968 | – |
| Bhaskar Anand | Chief Accounting Officer & Head of Finance | 1978 | – |
| Dave Gancarz | Chief Business & Strategy Officer | – | – |
| Elaine Carla Stracker | Chief Legal Officer | 1961 | – |
| Kay Elizabeth Davies | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | 1951 | – |
| Nathan LiaBraaten | Senior Director of Investor Relations | – | – |
| Robert LaCaze | Chief Commercial Officer | – | – |
| Urte Gayko | Chief Regulatory, Quality & Pharmacovigilance Officer | 1971 | – |
| Wang Clow Fong | Chief Biometrics Officer | 1958 | – |